Medication info
Empagliflozin/Metformin Extended-Release Tablets 12.5/1000 mg

Empagliflozin/Metformin Extended-Release Tablets 12.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Orange oval extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501903 · Approved 2025.07.24 · Insurance code 643508970

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride 2000 mg as extended-release formulation. To reduce gastrointestinal adverse reactions caused by metformin, take this medication once daily in the evening with a meal. Take 1 tablet of this medication as 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets once daily. Patients taking this medication as 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medications such as insulin, the recommended initial total daily dose when taking this medication is empagliflozin 10 mg and the patient’s current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this medication should receive their existing doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is co-administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function may be necessary, renal function should be assessed before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used by adjusting the dose of metformin hydrochloride as follows. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medication should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood sugar control issues in adult patients with type 2 diabetes
  • cardiovascular disease
View approved original text

This medication helps improve blood sugar control in adult patients with type 2 diabetes through the combined administration of empagliflozin and metformin. It is used as an adjunct to diet and exercise, particularly in patients whose blood sugar levels are not well controlled. The use of this medication is also recommended with caution in patients with type 2 diabetes who have accompanying cardiovascular disease. This medication plays a positive role in effectively managing blood sugar levels and preventing diabetes complications.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride 2000 mg as extended-release formulation. To reduce gastrointestinal adverse reactions caused by metformin, take this medication once daily in the evening with a meal. Take 1 tablet of this medication as 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets once daily. Patients taking this medication as 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medication whole; do not split, crush, grind, or chew it. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medications such as insulin, the recommended initial total daily dose when taking this medication is empagliflozin 10 mg and the patient’s current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this medication should receive their existing doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medication is co-administered with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dose adjustment based on renal function may be necessary, renal function should be assessed before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used by adjusting the dose of metformin hydrochloride as follows. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this medication should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication is used to treat type 2 diabetes and helps lower blood sugar levels. However, there are several important precautions to consider when using this medication. First, rare but serious lactic acidosis may occur, which can be life-threatening, so seek immediate medical advice if symptoms arise. Second, when used with other diabetes medications, there is a risk of hypoglycemia, so blood glucose levels should be closely monitored. Third, this medication should not be used in patients with impaired kidney function, severe infections, dehydration, or acute cardiac problems. Fourth, it should be temporarily discontinued in special situations such as surgery or radiological exams, and resumed only after kidney function has returned to normal. Fifth, it may cause fluid loss or dehydration, so caution is advised in the elderly or patients with low blood pressure. Sixth, there is an increased risk of urinary tract and genital infections, so prompt treatment is necessary if infection symptoms develop. Seventh, vitamin B12 deficiency can occur, so regular blood tests are recommended during long-term use. Eighth, this medication should be avoided in pregnant or potentially pregnant women, as well as in breastfeeding women. Ninth, it is not recommended for children or adolescents under 18 years of age as safety and efficacy have not been established. Lastly, this medication should be swallowed whole without crushing or chewing the tablets, and while the tablet shell may pass in the stool, this is normal. Patients should regularly monitor blood sugar and kidney function according to their physician's directives while using this medication, and seek immediate consultation with the medical team if any abnormal symptoms occur.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
Show 157 more
  • constipation
  • elevated liver function tests
  • hepatitis
  • taste disturbance
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • decreased and deficient vitamin B12
  • ketoacidosis
  • necrosis of the perineum
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic carcinoma
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colorectal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • salpingo-oophorectal abscess
  • vestibular neuritis
  • headache
  • dizziness
  • asthenia
  • chest discomfort
  • chest pain
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • urinary stones
  • hematuria
  • hypertonic bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • diabetic retinopathy
  • diplopia
  • hypertension
  • insomnia
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • position-induced vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • eye discomfort
  • conjunctival congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • lattice retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • skin laceration
  • contusion
  • rib fractures
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open eye injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal's angina
  • coronary artery disease
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • benign neoplasm of the Vater ampulla
  • benign ovarian tumor
  • bladder cancer
  • cholesteatoma
  • stomach cancer
  • leiomyoma
  • rectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Orange oval extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.